Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729778 · ClinicalTrials.gov registry record · Early Phase 1
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
A Early Phase 1 study of HIV Infections and HIV-1-infection, sponsored by VA Eastern Colorado Health Care System.
- Active
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03729778 is a Early Phase 1 study of HIV Infections and HIV-1-infection that is active but no longer recruiting, run by VA Eastern Colorado Health Care System. The registered enrollment target is 100 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03729778, a Early Phase 1 study of HIV Infections and HIV-1-infection, is active but no longer recruiting, sponsored by VA Eastern Colorado Health Care System.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
Conditions Studied
Interventions
- BIOLOGICAL Prevnar-13
Study Locations (1)
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2028-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03729778
The ClinicalTrials.gov registry entry for NCT03729778 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The listed sponsor is VA Eastern Colorado Health Care System, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Prevnar-13 is the first listed.
NCT03729778 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03729778 about?
NCT03729778 is a clinical study titled "Impact of HIV-1 and Aging on Mucosal Vaccine Responses". The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
What is the current status of trial NCT03729778?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2017-01-18. Estimated completion is 2028-01-01.
What conditions does trial NCT03729778 study?
This clinical trial studies the following conditions: HIV Infections, HIV-1-infection, HIV/AIDS, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT03729778?
The interventions under investigation include: Prevnar-13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03729778?
This trial is sponsored by VA Eastern Colorado Health Care System, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03729778 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Neuroinflammation FNOS PET/CT in HIV (+) and (-) Subjects With OUD and Healthy Controls
ACTIVE NOT RECRUITING · Early Phase 1
-
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
ACTIVE NOT RECRUITING · Early Phase 1
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.